The Biostatistics Shared Resource (BSR) continues to provide The Ohio State University Comprehensive Cancer Center (OSUCCC) investigators a centralized resource for biostatistical expertise. Statistical issues are addressed at all levels of investigation: from the design of experiments to the maintenance of data quality;and from conclusions based on formal hypothesis testing to important leads discovered by data exploration. In support of this objective, the specific aims of this resource include: 1) collaborate with OSUCCC investigators in planning and designing laboratory experiments, clinical trials, and population based studies;2) conduct statistical analysis of data generated by OSUCCC pilot projects, especially complex analysis and modeling needed for microarray studies and other types of high-dimensional data;3) identify innovative and effective statistical methods in response to specific project needs that will enhance the quality of design, interpretations, and communication of results;4) participate in all OSUCCC programs through administrative and research meetings to ensure that statistical issues are addressed;5) provide education regarding biostatistical considerations in study design and analysis in cancer research;and 6) verify and validate data quality of OSUCCC studies with the OSUCCC Clinical Trials Office, Biomedical Informatics, and the Behavioral Measurement Shared Resources.
These aims will be accomplished through proven successful approaches as well as newer approaches that respond to changes in technologies used by the research programs of the OSUCCC. For example, the BSR collaborated to set up a protocol to ensure integration across the three Shared Resources (Biostatistics, Biomedical Informatics and Microarray) for optimal support of OSUCCC investigators pursuing microarray expression studies. Over the past five years, the BSR has increased its collaborative integration into all programs. This has resulted in 1) BSR biostatisticians co-authoring over 200 cancer-related papers with OSUCCC investigators, which is more than double the number of publications cited in the previous renewal application;2) a substantial increase in the number of successful programmatic grant submissions (10 new programmatic grants with biostatistics cores, as well as in the total number of cancer grants supporting BSR biostatisticians (from 10 in 2004 to 35 in 2009), 3) 11 additional biostatisticians hired to support OSUCCC investigators, 4) increased sophistication in high-dimensional data analysis, and 5) greater presence and influence in planning meetings for laboratory science, population science, and clinical trials.
The Biostatistics Shared Resource (BSR) provides critical support for planning and design of experiments, clinical trials, and population based studies. These activities attempt to ensure that studies yield reliable conclusions and that resources are efficiently used. This support is especially important in grant proposals to show thorough planning, efficient and effective designs, and convincing analytic and hypothesis testing strategies. The BSR also provides the needed expertise for exploratory data analysis that enhances collaborative efforts for uncovering leads and for making optimal decisions about future studies.
|Fazio, Nicola; Buzzoni, Roberto; Baudin, Eric et al. (2016) A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. Anticancer Res 36:713-9|
|Eloy, Josimar O; Petrilli, Raquel; Topan, JosÃ© Fernando et al. (2016) Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy. Colloids Surf B Biointerfaces 141:74-82|
|Byrd, John C; Flynn, Joseph M; Kipps, Thomas J et al. (2016) Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood 127:79-86|
|Datta, Jharna; Islam, Mozaffarul; Dutta, Samidha et al. (2016) Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs. Oral Oncol 56:32-9|
|Wang, Hai; Agarwal, Pranay; Zhao, Shuting et al. (2016) Combined cancer therapy with hyaluronan-decorated fullerene-silica multifunctional nanoparticles to target cancer stem-like cells. Biomaterials 97:62-73|
|Villalona-Calero, Miguel A; Duan, Wenrui; Zhao, Weiqiang et al. (2016) Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. J Natl Cancer Inst 108:|
|Rai, K; Pilarski, R; Cebulla, C M et al. (2016) Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet 89:285-94|
|Kerrigan, Kathleen; Shoben, Abigail; Otterson, Gregory (2016) Treatment of Lung Cancer Patients With Actionable Mutations in the Intensive Care Unit. Clin Lung Cancer 17:523-527|
|DiSilvestro, David J; Melgar-Bermudez, Emiliano; Yasmeen, Rumana et al. (2016) Leptin Production by Encapsulated Adipocytes Increases Brown Fat, Decreases Resistin, and Improves Glucose Intolerance in Obese Mice. PLoS One 11:e0153198|
|Terakawa, Jumpei; Rocchi, Altea; Serna, Vanida A et al. (2016) FGFR2IIIb-MAPK Activity Is Required for Epithelial Cell Fate Decision in the Lower MÃ¼llerian Duct. Mol Endocrinol 30:783-95|
Showing the most recent 10 out of 1929 publications